meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
5
mNSCLC - L2 - adenocarcinoma cell
mNSCLC - L2 - all population
5
mNSCLC - L2 - EGFR high
mNSCLC - L2 - EGFR mutant
1
mNSCLC - L2 - EGFR wild type
mNSCLC - L2 - KRAS mutant
mNSCLC - L2 - KRAS wild type
mNSCLC - L2 - PDL1 negative
1
mNSCLC - L2 - PDL1 positive
7
non squamous cell - mNSCLC - L2
non squamous - mNSCLC - L2 - all population
1
non squamous - mNSCLC - L2 - EGFR mutant
non squamous - mNSCLC - L2 - PDL1 positive
non squamous - mNSCLC - L2 - wild type (WT)
squamous cell - mNSCLC - L2
squamous - mNSCLC - L2 - all population
1
squamous - mNSCLC - L2 - PDL1 positive
<span style="margin-left: 0em;">chemotherapy</span>
<span style="margin-left: 1em;">non platinum-based chemotherapy</span>
<span style="margin-left: 2em;">taxanes</span>
<span style="margin-left: 3em;">docetaxel <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">nivolumab based treatment</span>
<span style="margin-left: 3em;">nivolumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (1)
progression or deaths (PFS) (1)
objective responses (ORR) (1)
deaths (OS) (extension) (1)
DOR (1)
PFS (extension) (1)
objective responses (ORR) (extension) (1)
DOR (extension) (1)
TRAE (any grade) (1)
TRAE leading to discontinuation (grade 3-4) (1)
TRAE (grade 3-4) (1)
TRAE leading to death (grade 5) (1)
TRAE leading to discontinuation (any grade) (1)
SAE (grade 3-4) (1)
STRAE (any grade) (1)
Nausea TRAE (grade 3-4) (1)
Arthralgia TRAE (grade 3-4) (1)
Anaemia TRAE (grade 3-4) (1)
Decreased appetite TRAE (grade 3-4) (1)
Asthenia TRAE (grade 3-4) (1)
Pyrexia TRAE (grade 3-4) (1)
Pneumonitis TRAE (grade 3-4) (1)
Neutropenia TRAE (grade 3-4) (1)
Vomiting TRAE (grade 3-4) (1)
Constipation TRAE (grade 3-4) (1)
Paraesthesia TRAE (grade 3-4) (1)
Leucopenia TRAE (grade 3-4) (1)
Alopecia TRAE (grade 3-4) (1)
Abdominal pain TRAE (grade 3-4) (1)
Myalgia TRAE (grade 3-4) (1)
Peripheral neuropathy TRAE (grade 3-4) (1)
Peripheral oedema TRAE (grade 3-4) (1)
Mucosal inflammation TRAE (grade 3-4) (1)
Rash TRAE (grade 3-4) (1)
Diarrhoea TRAE (grade 3-4) (1)
Febrile neutropenia TRAE (grade 3-4) (1)
Fatigue TRAE (grade 3-4) (1)
Dizziness TRAE (grade 3-4) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for deaths (OS)
1
CheckMate 017, 2015
docetaxel
nivolumab alone
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
docetaxel
nivolumab alone
docetaxel
---
NA
nivolumab alone
NA
---
pathologies: 280,168,169 - treatments: 360,719,721,720
result logic
×
Study list
